NCT04947033招募中1 期
A Phase I Clinical Study Evaluating the Safety, Tolerability, MTD or MAD, PK, PD, and Antitumor Activity of TJ210001(a Fully Human C5aR Monoclonal Antibody) in Subjects With Advanced Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- Rate and Severity of Dose-limiting toxicity （DLT）
研究概览
简要总结
A phase I clinical study evaluating TJ210001 in the treatment of subjects with advanced solid tumors
详细描述
This study is a phase I clinical study evaluating TJ210001 monotherapy in patients with advanced solid tumors in dose escalation. The overall design of the study is shown in the figure below. The purpose of the TJ210001 single-dose escalation study in subjects with advanced solid tumors is to evaluate the safety and tolerability of monotherapy to determine the MTD (or MAD) and clinically recommended doses of TJ210001 monotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- •Have received chemotherapy, radiotherapy, biological therapy, endocrine therapy, immunotherapy and other anti-tumor treatments within 4 weeks before the first administration of the study drug, except for the following items:
- •Nitrosourea or Mitomycin C has been used within 6 weeks before the first administration of the study drug;
- •Oral fluorouracil and small molecule targeted drugs are used 2 weeks before the first administration of the study drug or 5 half-lives of the drug (whichever is longer);
- •Chinese medicine with anti-tumor indications is used within 2 weeks before the first administration of the study drug.
- •Have received other unmarketed clinical study drugs or treatments within 4 weeks before the first administration of the study drug;
- •Have received major organ surgery (excluding needle biopsy) or significant trauma within 4 weeks before the first administration of the study drug, or the elective surgery will be required during the study period;
- •Have received systemic glucocorticoids (prednisone> 10 mg/day or equivalent doses of similar drugs) or other immunosuppressive agents within 14 days before the first administration of the study drug; Except for the following situations: Use topical, eye, intra-articular, intranasal and inhaled glucocorticoid therapy; short-term use of glucocorticoid for preventive treatment (such as prevention of contrast agent allergy)
- •Have received immunomodulatory drugs, including but not limited to thymosin, interleukin-2, interferon, etc. within 14 days before the first administration of study drug;
- •Have received the live attenuated vaccine within 4 weeks before the first administration of study drug;
- •Have received C5aR inhibitor treatment in the past;
- •Those who have previously received allogeneic hematopoietic stem cell transplantation or organ transplantation;
- •The adverse reactions of previous anti-tumor treatments have not yet recovered to CTCAE 5.0 grade evaluation ≤ grade 1 (except for the toxicity that the investigator judges to have no safety risk, such as alopecia, grade 2 peripheral neurotoxicity, etc.);
- •Patients with central nervous system metastasis or meningeal metastasis with clinical symptoms, or other evidence indicates that the patient's central nervous system metastasis or meningeal metastasis has not been controlled, and those who are judged by the investigators to be unsuitable for inclusion;
- •Those who have an active infection 1 week before the first administration of the study drug and currently require systemic anti-infective treatment;
- •Have a history of immunodeficiency, including HIV antibody test positive ;
- •Active hepatitis B (HBsAg positive and HBV-DNA > the lower limit of detection of the study center). For subjects who are HBsAg positive but HBV-DNA negative, if the antiviral therapy is needed judged by investigator, the subjects will not be excluded; Hepatitis C virus infection (anti-HCV positive);
- •Patients currently suffering from interstitial lung disease;
- •Have a history of severe cardiovascular and cerebrovascular diseases, including but not limited to:
- •Have severe heart rhythm or conduction abnormalities, such as ventricular arrhythmia that requires clinical intervention, grade Ⅱ-Ⅲ atrioventricular block;
- •Acute coronary syndrome, congestive heart failure, aortic dissection, stroke, or other grade 3 or above cardiovascular and cerebrovascular events occurred within 6 months before the first administration of study drug;
- •Patients with the New York Heart Association (NYHA) heart function classification ≥ Grade II;
- •Have clinically uncontrollable hypertension;
- •Patients with active, or have had autoimmune diseases that may have recurrence (such as systemic lupus erythematosus, rheumatoid arthritis, vasculitis), except for patients with clinically stable autoimmune thyroid disease;
- •Patients who have received immunotherapy and have irAE grade ≥ grade 3;
- •Patients who have clinically uncontrollable fluid in the third space and who are judged by the investigator to be unsuitable for enrollment;
- •Patients who are known to have alcohol or drug dependence;
- •Patients with mental disorders or poor compliance;
- •Pregnant or lactating women;
- •The subjects who are considered by investigators to have a history of other serious systemic diseases or other reasons are not suitable to participate in this clinical study."
研究组 & 干预措施
TJ210001 Injection
Experimental
Single Arm Dose expansion
干预措施: TJ210001 Injection (Drug)
结局指标
主要结局
Rate and Severity of Dose-limiting toxicity （DLT）
时间窗: up to 28 days after last dose of study drug
Maximum tolerated dose (MTD)
时间窗: up to 21days following first dose
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid TumorsSolid TumorMetastatic CancerAdvanced CancerNCT04678921I-Mab Biopharma US Limited16
进行中（未招募）
1 期
Phase 1 Study Evaluating VT1021 in Patients With Advanced Solid TumorsSolid TumorNCT03364400Vigeo Therapeutics, Inc.116
已完成
1 期
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With CancerAcute Myeloid Leukemia (AML)Non-Hodgkins LymphomaBreast CancerCancerProstate CancerMultiple MyelomaNon-Small Cell Lung CancerSmall Cell Lung CancerNCT02391480AbbVie128
已完成
1 期
An Phase I Study of YY001 in Patients with Advanced Solid TumorsAdvanced Solid TumorNCT06228846Shanghai Yuyao Biotech Co., Ltd.16
撤回
1 期
Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese ParticipantsSolid TumorsNCT05644626BeiGene